Cargando…
Amyloidogenesis: What Do We Know So Far?
The study of protein aggregation, and amyloidosis in particular, has gained considerable interest in recent times. Several neurodegenerative diseases, such as Alzheimer’s (AD) and Parkinson’s (PD) show a characteristic buildup of proteinaceous aggregates in several organs, especially the brain. Desp...
Autores principales: | Alraawi, Zeina, Banerjee, Nayan, Mohanty, Srujana, Kumar, Thallapuranam Krishnaswamy Suresh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695042/ https://www.ncbi.nlm.nih.gov/pubmed/36430450 http://dx.doi.org/10.3390/ijms232213970 |
Ejemplares similares
-
Eosinophilic Esophagitis—What Do We Know So Far?
por: Wąsik, Jakub, et al.
Publicado: (2023) -
HIV and neoplasms: What do we know so far?
por: de Souza, Thais Faria, et al.
Publicado: (2023) -
The effects of huntingtin-lowering: what do we know so far?
por: Kaemmerer, William F, et al.
Publicado: (2019) -
COVID-19 and Myocarditis: What Do We Know So Far?
por: Pirzada, Ashar, et al.
Publicado: (2020) -
Electronic Cigarettes and Asthma: What Do We Know So Far?
por: Kotoulas, Serafeim-Chrysovalantis, et al.
Publicado: (2021)